Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Alterations of ubiquitin related proteins in the pathology and development of schizophrenia: Evidence from human and animal studies.

Andrews JL, Goodfellow FJ, Matosin N, Snelling MK, Newell KA, Huang XF, Fernandez-Enright F.

J Psychiatr Res. 2017 Jul;90:31-39. doi: 10.1016/j.jpsychires.2017.01.009. Epub 2017 Jan 18.

PMID:
28226265
2.

Molecular evidence of synaptic pathology in the CA1 region in schizophrenia.

Matosin N, Fernandez-Enright F, Lum JS, Engel M, Andrews JL, Gassen NC, Wagner KV, Schmidt MV, Newell KA.

NPJ Schizophr. 2016 Jun 29;2:16022. doi: 10.1038/npjschz.2016.22. eCollection 2016.

3.

Lingo-1: a novel target in therapy for Alzheimer's disease?

Fernandez-Enright F, Andrews JL.

Neural Regen Res. 2016 Jan;11(1):88-9. doi: 10.4103/1673-5374.175048. No abstract available.

4.

Genetic variants in Nogo receptor signaling pathways may be associated with early life adversity in schizophrenia susceptibility.

Andrews JL, Fernandez-Enright F.

BBA Clin. 2014 Dec 9;3:36-43. doi: 10.1016/j.bbacli.2014.11.008. eCollection 2015 Jun.

5.

Possibility of a sex-specific role for a genetic variant in FRMPD4 in schizophrenia, but not cognitive function.

Matosin N, Green MJ, Andrews JL, Newell KA, Fernandez-Enright F.

Neuroreport. 2016 Jan 6;27(1):33-8. doi: 10.1097/WNR.0000000000000491.

PMID:
26555035
6.

Shifting towards a model of mGluR5 dysregulation in schizophrenia: Consequences for future schizophrenia treatment.

Matosin N, Fernandez-Enright F, Lum JS, Newell KA.

Neuropharmacology. 2017 Mar 15;115:73-91. doi: 10.1016/j.neuropharm.2015.08.003. Epub 2015 Sep 6. Review.

PMID:
26349010
7.

A decade from discovery to therapy: Lingo-1, the dark horse in neurological and psychiatric disorders.

Andrews JL, Fernandez-Enright F.

Neurosci Biobehav Rev. 2015 Sep;56:97-114. doi: 10.1016/j.neubiorev.2015.06.009. Epub 2015 Jul 2. Review.

PMID:
26143511
8.

Alterations of p75 neurotrophin receptor and Myelin transcription factor 1 in the hippocampus of perinatal phencyclidine treated rats.

Andrews JL, Newell KA, Matosin N, Huang XF, Fernandez-Enright F.

Prog Neuropsychopharmacol Biol Psychiatry. 2015 Dec 3;63:91-7. doi: 10.1016/j.pnpbp.2015.06.003. Epub 2015 Jun 10.

PMID:
26071990
9.

Metabotropic glutamate receptor 5, and its trafficking molecules Norbin and Tamalin, are increased in the CA1 hippocampal region of subjects with schizophrenia.

Matosin N, Fernandez-Enright F, Lum JS, Andrews JL, Engel M, Huang XF, Newell KA.

Schizophr Res. 2015 Aug;166(1-3):212-8. doi: 10.1016/j.schres.2015.05.001. Epub 2015 Jun 2.

PMID:
26048293
10.

Alterations of mGluR5 and its endogenous regulators Norbin, Tamalin and Preso1 in schizophrenia: towards a model of mGluR5 dysregulation.

Matosin N, Fernandez-Enright F, Fung SJ, Lum JS, Engel M, Andrews JL, Huang XF, Weickert CS, Newell KA.

Acta Neuropathol. 2015 Jul;130(1):119-29. doi: 10.1007/s00401-015-1411-6. Epub 2015 Mar 17.

PMID:
25778620
11.

Investigation of genetic variants in ubiquitin enzyme genes involved in the modulation of neurodevelopmental processes: a role in schizophrenia susceptibility?

Andrews JL, Fernandez-Enright F.

Genet Res (Camb). 2014 Nov 24;96:e15. doi: 10.1017/S0016672314000184.

PMID:
25578144
13.

Novel implications of Lingo-1 and its signaling partners in schizophrenia.

Fernandez-Enright F, Andrews JL, Newell KA, Pantelis C, Huang XF.

Transl Psychiatry. 2014 Jan 21;4:e348. doi: 10.1038/tp.2013.121.

14.

In vivo pharmacological evaluations of novel olanzapine analogues in rats: a potential new avenue for the treatment of schizophrenia.

Jafari S, Huang XF, Andrews JL, Fernandez-Enright F.

PLoS One. 2013 Dec 11;8(12):e80979. doi: 10.1371/journal.pone.0080979. eCollection 2013.

15.

Novel olanzapine analogues presenting a reduced H1 receptor affinity and retained 5HT2A/D2 binding affinity ratio.

Jafari S, Bouillon ME, Huang XF, Pyne SG, Fernandez-Enright F.

BMC Pharmacol. 2012 Jun 22;12:8. doi: 10.1186/1471-2210-12-8.

16.

Structural contributions of antipsychotic drugs to their therapeutic profiles and metabolic side effects.

Jafari S, Fernandez-Enright F, Huang XF.

J Neurochem. 2012 Feb;120(3):371-84. doi: 10.1111/j.1471-4159.2011.07590.x. Epub 2011 Dec 15. Review.

Supplemental Content

Loading ...
Support Center